
Veran Medical Technologies
Total Raised
$156.25MInvestors Count
16Deal Terms
3Funding, Valuation & Revenue
12 Fundings
Veran Medical Technologies has raised $156.25M over 12 rounds.
Veran Medical Technologies's latest funding round was a Acquired for on December 4, 2020.
Veran Medical Technologies's latest post-money valuation is from December 2020.
Sign up for a free demo to see Veran Medical Technologies's valuations in December 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/4/2020 | Acquired | 5 | ||||
12/19/2018 | Line of Credit | $35M | 1 | |||
11/13/2018 | Corporate Minority | $20M | 3 | |||
12/21/2016 | Series F | |||||
12/21/2016 | Debt - II |
Date | 12/4/2020 | 12/19/2018 | 11/13/2018 | 12/21/2016 | 12/21/2016 |
|---|---|---|---|---|---|
Round | Acquired | Line of Credit | Corporate Minority | Series F | Debt - II |
Amount | $35M | $20M | |||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 5 | 1 | 3 |
Veran Medical Technologies Deal Terms
3 Deal Terms
Veran Medical Technologies's deal structure is available for 3 funding rounds, including their Acquired from December 04, 2020.
Round | Acquired | Series B - II | Series B |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired | |||||||||||||||
Series B - II | |||||||||||||||
Series B |
Veran Medical Technologies Investors
16 Investors
Veran Medical Technologies has 16 investors. Olympus invested in Veran Medical Technologies's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
12/4/2020 | 12/4/2020 | 1 Acquired | Corporation | Japan | ||
12/19/2018 | 12/19/2018 | 1 Line of Credit | Private Equity | New York | ||
11/13/2018 | 11/13/2018 | 1 Corporate Minority | Corporation | United Kingdom | ||
Growth Equity | Ohio | |||||
Venture Capital | California |
First funding | 12/4/2020 | 12/19/2018 | 11/13/2018 | ||
|---|---|---|---|---|---|
Last Funding | 12/4/2020 | 12/19/2018 | 11/13/2018 | ||
Investor | |||||
Rounds | 1 Acquired | 1 Line of Credit | 1 Corporate Minority | ||
Board Seats | |||||
Type | Corporation | Private Equity | Corporation | Growth Equity | Venture Capital |
Location | Japan | New York | United Kingdom | Ohio | California |
Compare Veran Medical Technologies to Competitors

CIVCO Medical Solutions is involved in medical technology related to ultrasound products and services. The company provides products such as ultrasound probe covers, cleaning and disinfection systems, needle guides, and solutions for transperineal prostate procedures. CIVCO's technology aims to address infection control, enhance imaging procedures, and assist during ultrasound interventions. It is based in Kalona, Iowa.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
RadioTherapeutics Corporation is developing tools for minimally invasive treatment of solid tumors. The RF 2000B is used by surgeons, interventional radiologists, and gastroenterologists to predictably, precisely and homogeneously ablate diseased or unwanted volumes of soft tissues.
News of a breast biopsy raises many emotions and concerns. The company understand. But it's important to remember that 80% of breast biopsies do not turn out to be breast cancer. It's also important to know that users have options when selecting a biopsy procedure. This site is dedicated to evaluating their choices to help users talk with their doctor about the breast biopsy procedure that is right for users. One of those choices is a minimally invasive breast biopsy for breast cancer diagnosis using the Mammotome Breast Biopsy System. Mammotome is made available by Ethicon Endo-Surgery, Inc.
BioSpiral's state-of-art system aims to provide prostate cancer treatment as a minimally invasive procedure, which uses cooling & heating technologies to destroy prostate cancer.nBioSpiral was established in Sep 2006 and is operating as part of NGT Incubator. nBioSpiral prostate thermodynamics therapy is an effective, minimally invasive treatment for prostate cancer that does not involve the difficulty and complications associated with surgery, nor the harmful properties of radiation or cryotherapy .The system revolutionizes prostate cancer treatment by introducing a "one shot" treatment method under local anesthesia at the physician's clinic. BioSpiral treatment is for patients with localized prostate cancer, who look for an effective minimal invasive therapy for prostate cancer. Additionally, this treatment can also be used by patients who have local recurrence after other treatments ("salvage" treatment). Key advantages:nCost effective: short treatment, no need for O.R or hospitalizationnHighly efficient: tissue ablationnPatients: high quality of life; minimal side effects, minimal invasive, short treatment & recovery.
Tomophase Corporation was founded with the mission of developing solutions for minimally invasive diagnostic (MID) imaging. The company is using light to guide new ways of diagnosing diseases and has conceived major ideas for an optical MID imaging system
Loading...

